Tag: antipsychotic
MedinCell: start of the Phase 3 study for the second long-acting injectable antipsychotic
Through Olivier Cheilan Published on 01/24/2023 at 6:20 p.m. (Boursier.com) —…
Launch of a phase 3 study for the second long-acting injectable antipsychotic using MedinCell technology – 08/29/2022 at 18:00
Teva Pharmaceuticals has informed MedinCell of its decision to initiate the Phase 3 clinical trial for mdc-TJK. MedinCell will immediately receive a $3 million payment from Teva Pharmaceuticals for reaching…